EMERGENT BIOSOLUTIONS INC (EBS)       13.47  +0.35 (+2.67%)

13.47  +0.35 (+2.67%)

US29089Q1058 - Common Stock - After market: 14.15 +0.68 (+5.05%)

EMERGENT BIOSOLUTIONS INC13.47

NYSE:EBS (1/27/2023, 7:04:00 PM)+0.35 (+2.67%)

After market: 14.15 +0.68 (+5.05%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 01-09 2023-01-09 Earnings (Next) 04-26 2023-04-26
Ins Owners 2.04% Inst Owners 81.92%
Market Cap 671.99M Shares 49.89M
PE 5.28 Fwd PE 17.04
Dividend Yield N/A Analysts 70.91
IPO 11-15 2006-11-15

Stock Screener Links

Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

EBS Daily chart

Company Profile

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,416 full-time employees. The company went IPO on 2006-11-15. The firm is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. The company provides solutions for PHTs through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. The company offers TEMBEXA (brincidofovir) an antiviral for the treatment of smallpox in all age groups, including adults, and for patients who have difficulty swallowing.

Company Info

EMERGENT BIOSOLUTIONS INC

400 Professional Dr, Suite 400

Gaithersburg MARYLAND 20879

P: 12406313200.0

CEO: Robert G. Kramer

Employees: 2416

Website: https://emergentbiosolutions.com/

EBS News

News Image11 days ago - MarketBeatJohnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?

Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.

News Image20 days ago - Emergent BioSolutionsEmergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic FocusNews Image24 days ago - Seeking AlphaEmergent BioSolutions (NYSE:EBS) gets ~$380M military contract

Emergent BioSolutions (EBS) has been awarded a contract valued up to ~$380M to supply skin decontamination lotion kits for use by all branches of the U.S. military. Read more here.

News Image24 days ago - Emergent BioSolutionsEmergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of DefenseNews Image24 days ago - Emergent BioSolutionsEmergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense

GAITHERSBURG, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an indefinite-delivery,...

News Image2 months ago - Market News VideoEmergent BioSolutions is Now Oversold (EBS)

EBS Twits

Here you can normally see the latest stock twits on EBS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example